| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CST2 |
| Uniprot No | P09228 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-141aa |
| 氨基酸序列 | WSPQEEDRIIEGGIYDADLNDERVQRALHFVISEYNKATEDEYYRRLLRV LRAREQIVGGVNYFFDIEVGRTICTKSQPNLDTCAFHEQPELQKKQLCSF QIYEVPWEDRMSLVNSRCQEA |
| 预测分子量 | 15 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与CST2重组蛋白相关的假设性参考文献(注：CST2相关研究较少，以下内容为模拟示例，实际文献需通过学术数据库检索确认)：
1. **文献名称**：*"Recombinant human CST2 protein inhibits tumor growth in oral squamous cell carcinoma"*
**作者**：Zhang Y. et al. (2020)
**摘要**：研究通过大肠杆菌系统表达CST2重组蛋白，发现其通过调控EGFR信号通路抑制口腔鳞癌细胞增殖，提示其潜在抗癌作用。
2. **文献名称**：*"Expression and functional characterization of CST2 in salivary gland inflammation"*
**作者**：Li X. et al. (2018)
**摘要**：利用哺乳动物细胞表达CST2重组蛋白，证实其通过抑制半胱氨酸蛋白酶活性减轻唾液腺炎症反应，可能作为炎症治疗靶点。
3. **文献名称**：*"Structural analysis of CST2 reveals its role in dental enamel formation"*
**作者**：Wang R. et al. (2021)
**摘要**：通过昆虫细胞系统获得高纯度CST2重组蛋白，解析其晶体结构，揭示其与牙釉质基质蛋白相互作用的分子机制。
**注意**：以上为模拟文献，CST2(Cystatin SA-II)实际研究多集中于口腔生物学领域，建议通过PubMed或Google Scholar以关键词“CST2 recombinant protein”或“Cystatin SA-II expression”检索真实文献。
**Background of CST2 Recombinant Protein**
CST2 (Cystatin-SA2) is a member of the cystatin superfamily, a group of cysteine protease inhibitors that regulate proteolytic enzymes like cathepsins. These inhibitors play critical roles in maintaining protease-antiprotease balance, impacting physiological processes such as tissue remodeling, immune response, and inflammation. CST2 is primarily expressed in salivary glands and mucosal tissues, suggesting its involvement in oral homeostasis, antimicrobial defense, and protection against pathological proteolysis.
Structurally, CST2 contains conserved cystatin-like domains, enabling tight binding to cysteine proteases via a tripartite interaction motif. Its inhibitory activity helps modulate excessive protease activity linked to inflammatory diseases, tumor progression, or microbial infections. Dysregulation of CST2 has been implicated in conditions like periodontitis and certain cancers, highlighting its therapeutic potential.
Recombinant CST2 protein is produced using biotechnological platforms (e.g., *E. coli* or mammalian expression systems) to ensure high purity and bioactivity. The recombinant form retains native inhibitory properties, making it valuable for *in vitro* studies, drug discovery, and diagnostic applications. Researchers utilize CST2 to investigate protease-dependent pathways, develop enzyme-targeted therapies, or explore biomarkers for disease monitoring.
Current research focuses on optimizing CST2’s stability and delivery for therapeutic use, particularly in inflammatory disorders or as an adjunct in cancer treatment. Its role in modulating immune responses and tissue repair further underscores its versatility in biomedical applications. As a tool protein, recombinant CST2 continues to advance both basic and translational studies in proteolysis-related diseases.
(Word count: 199)
×
